Phase 3 randomized controlled trial (RCT) data for Aqp-4-positive NMOSD (PREVENT, prevention of relapses in neuromyelitis optica; NCT01892345) showed a remarkable 94% relative risk reduction of relapses (53) however the benefits were less clear in the RCT data for MG. The gene discussed is AQP4; the disease is myasthenia gravis.